Morgan Stanley notes STAT News’ report yesterday that a group of reviewers at the FDA did not want to approve SRP-9001 and that Peter Marks stepped in and scheduled an advisory committee meeting, or AdCom. Following STAT’s report, the analyst does not find tension among FDA staff surprising and "would expect it throughout the review process." However, the firm expects a supportive AdCom based on the evidence supporting the surrogate endpoint and while it continues to expect volatility through then, Morgan Stanley expects "ultimate approval" for SRP-9001. The firm has an Overweight rating and $183 price target on Sarepta shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT:
- Wave Life selloff on Sarepta article ‘makes no sense,’ says Mizuho
- Opco says buy Sarepta on selloff, views unchanged after article
- Sarepta volatility ‘name of the game’ into AdCom and PDUFA date, says Guggenheim
- Sarepta Drops as Report Hints at Opposition from FDA to its Gene Therapy
- Baird sees no change to Sarepta AdCom outlook amid ‘drama’ from report